Related Experiment Video

Updated: Jun 26, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Clinical Use of PPARgamma Ligands in Cancer

Jennifer L Hatton1, Lisa D Yee

  • 1Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH 43210, USA.

PPAR Research
|January 7, 2009
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands show promise as anticancer agents. These compounds, particularly thiazolidinediones, demonstrate antiproliferative and differentiating effects in various solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear receptor, plays a key role in adipocyte differentiation.
  • Its function in regulating malignant cell growth and differentiation has garnered significant research interest.
  • PPARgamma ligands exhibit antiproliferative and differentiating effects on liposarcoma cells.

Purpose of the Study:

  • To review the clinical applications of PPARgamma ligands in cancer therapy and prevention.
  • To explore the potential of PPARgamma activation in treating various solid tumors.
  • To focus on thiazolidinediones as a specific class of PPARgamma ligands for cancer treatment.

Main Methods:

  • Review of existing literature on PPARgamma ligands and their effects on cancer cells.
  • Analysis of studies investigating PPARgamma expression and ligand activation in breast, colon, and prostate cancers.
  • Examination of preclinical data from cell culture and rodent models.

Main Results:

  • PPARgamma ligands demonstrate anticancer effects across multiple tumor types.
  • Evidence suggests broad applicability of these agents in cancer therapy.
  • Thiazolidinediones show potential for both treatment and prevention of cancer.

Conclusions:

  • PPARgamma ligands, especially thiazolidinediones, represent a promising therapeutic strategy for cancer.
  • Further clinical investigation is warranted to establish their role in cancer treatment and prevention.
  • The findings support the broad applicability of PPARgamma-targeting agents in oncology.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...